Commodity Channel Index
|Bid||72.73 x 1000|
|Ask||74.41 x 2200|
|Day's Range||73.50 - 74.67|
|52 Week Range||64.75 - 89.72|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||21.02|
|Earnings Date||Jul 31, 2023 - Aug 04, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||84.00|
Subscribe to Yahoo Finance Plus to view Fair Value for HSICLearn more
MELVILLE, N.Y., May 17, 2023--Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, delivered the commencement address on May 12, 2023, at the University of North Carolina at Chapel Hill Adams School of Dentistry.
MELVILLE, N.Y., May 17, 2023--Henry Schein to participate in three investor conferences.
Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.
Q1 2023 Henry Schein Inc Earnings Call
Henry Schein Inc (NASDAQ: HSIC) posts Q1 FY23 sales of $3.06 billion, slightly missing the consensus of $3.09 billion, down 3.8% Y/Y, including 3.7% decrease in local currencies excluding acquisitions, 1.4% growth from acquisitions and a 1.5% decrease related to foreign currency exchange. Sales of PPE products and COVID-19 test kits in the first quarter were $201 million, a decrease of $287 million versus the prior-year period. When excluding sales of PPE products and COVID-19 test kits, first-q
Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.
Henry Schein (HSIC) delivered earnings and revenue surprises of -2.42% and 1.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MELVILLE, N.Y., May 09, 2023--Henry Schein reports first-quarter 2023 financial results.
Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
MELVILLE, N.Y., May 07, 2023--Henry Schein acquires Regional Health Care Group, a medical distributor serving the Australia and New Zealand region.
It is hard to get excited after looking at Henry Schein's (NASDAQ:HSIC) recent performance, when its stock has declined...
MELVILLE, N.Y., May 04, 2023--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care products and services to office-based dental and medical practitioners, announced an agreement to acquire S.I.N. Implant System, one of Brazil’s leading manufacturers of dental implants, pending regulatory approval.
Henry Schein (HSIC) closed the most recent trading day at $80.01, moving -0.58% from the previous trading session.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MELVILLE, N.Y., May 03, 2023--Henry Schein Dental Presents: THRIVELIVE 2023
Henry Schein (HSIC) closed at $81.19 in the latest trading session, marking a -0.02% move from the prior day.
Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
West Pharmaceutical Services, The Cooper Companies and Henry Schein have been highlighted in this Industry Outlook article.
Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.
The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.
Here, we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, COO and HSIC.
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.